Is Tumor Mutation Burden a predictive Marker for AJCC Stage II Melanoma?

被引：0
|
作者：
Sinnberg, T. [1 ]
Niessner, H. [1 ]
Amaral, T. [1 ,2 ]
Eigentler, T. [1 ]
Schroeder, C. [3 ]
Lindner, E. S. [3 ]
Hilke, F. J. [3 ,4 ]
Bonzheim, I. [5 ]
Fend, F. [5 ]
Riess, O. [3 ]
Garbe, C. [1 ]
机构：
[1] Univ Hautklin Tubingen, Zentrum Dermatoonkol, Tubingen, Germany
[2] Portuguese Air Force, Hlth Care Direct, Lisbon, Portugal
[3] Univ Klinikum Tubingen, Inst Med Genet & Angew Genom, Tubingen, Germany
[4] Charite Univ Med Berlin, Dermatol, Berlin, Germany
[5] Univ Klinikum Tubingen, Inst Pathol, Tubingen, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2020年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV34
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [21] Predictive Marker in malignant Melanoma
    Weide, B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 37 - 37
  • [22] Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer
    Betge, Johannes
    Kornprat, Peter
    Pollheimer, Marion J.
    Lindtner, Richard A.
    Schlemmer, Andrea
    Rehak, Peter
    Vieth, Michael
    Langner, Cord
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (12) : 3706 - 3712
  • [23] Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer
    Johannes Betge
    Peter Kornprat
    Marion J. Pollheimer
    Richard A. Lindtner
    Andrea Schlemmer
    Peter Rehak
    Michael Vieth
    Cord Langner
    Annals of Surgical Oncology, 2012, 19 : 3706 - 3712
  • [24] The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
    Ning, Biao
    Liu, Yixin
    Wang, Miao
    Li, Yi
    Xu, Tianzi
    Wei, Yongchang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [25] Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed
    Meng, Xiang-Yu
    Wu, Qiu-Ji
    EPIGENOMICS, 2023, 15 (22) : 1175 - 1178
  • [26] Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden
    Lin, Jiaqiong
    Lin, Yan
    Huang, Zena
    Li, Xiaoyong
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2020, 2020
  • [27] Circulating tumor DNA mutation as a prognostic marker in melanoma with brain metastasis.
    Behera, Tapas Ranjan
    Song, Jung Min
    Eicher, Donald Matthew
    Gastman, Brian
    Farkas, Daniel H.
    Funchain, Pauline
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Immune checkpoint inhibitors and tumor mutation burden as predictive biomarkers in hepatocellular carcinoma
    Shrestha, R.
    Prithviraj, P.
    Bridle, K. R.
    Crawford, D. H. G.
    Anaka, M.
    Jayachandran, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 31 - 31
  • [29] The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma
    Wang, Xuefeng
    Yu, Xiaoqing
    Krauthammer, Michael
    Hugo, Willy
    Duan, Chunzhe
    Kanetsky, Peter A.
    Teer, Jamie K.
    Thompson, Zachary J.
    Kalos, Denise
    Tsai, Kenneth Y.
    Smalley, Keiran Sm
    Sondak, Vernon K.
    Chen, Y. Ann
    Conejo-Garcia, Jose R.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (09) : 1792 - 1799
  • [30] Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
    Versluis, Judith M.
    Blankenstein, Stephanie A.
    Dimitriadis, Petros
    Wilmott, James S.
    Elens, Robert
    Blokx, Willeke A. M.
    van Houdt, Winan
    Menzies, Alexander Maxwell
    Schrage, Yvonne M.
    Wouters, Michel W. J. M.
    Sanders, Joyce
    Broeks, Annegien
    Scolyer, Richard A.
    Suijkerbuijk, Karijn P. M.
    Long, Georgina, V
    van Akkooi, Alexander C. J.
    Blank, Christian U.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
12345